<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218072</url>
  </required_header>
  <id_info>
    <org_study_id>HLX01-NHL01</org_study_id>
    <nct_id>NCT03218072</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas</brief_title>
  <official_title>A Phase Ia, Multi-centers, Open-label, Dose-escalation Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Potential Rituximab Biosimilar) in Patients With CD20-positive B-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <brief_summary>
    <textblock>
      To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a potential&#xD;
      rituximab biosimilar) in patients with CD20-positive B-cell lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase Ia, multicenter, open-label, dose-escalation clinical study to evaluate the&#xD;
      safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of HLX01&#xD;
      injection in patients with CD20-positive B-cell lymphomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2014</start_date>
  <completion_date type="Actual">January 31, 2015</completion_date>
  <primary_completion_date type="Actual">January 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>From First infusion to Day 90</time_frame>
    <description>The type, severity and incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>From First infusion to Day 90</time_frame>
    <description>Thetype, severity and incidence of SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>Area under the serum concentration-time curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD19 positive B cells</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The count of CD19 positive in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD20 positive B cells</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The count of CD20 positive in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies of HLX01</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The concentration of anti-HLX01 in serum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>B-cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>HLX01 250 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 250 mg/m2 administrated intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX01 375 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 375 mg/m2 administrated intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX01 500 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 500 mg/m2 administrated intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX01</intervention_name>
    <description>a potential rituximab biosimilar</description>
    <arm_group_label>HLX01 250 mg/m2</arm_group_label>
    <arm_group_label>HLX01 375 mg/m2</arm_group_label>
    <arm_group_label>HLX01 500 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years ≤ aged ≤ 65 years, male or female;&#xD;
&#xD;
          -  having histologically confirmed diagnosis of relapsed/refractory CD20-positive B-cell&#xD;
             lymphomas which needed consolidation therapy;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status≤1 and life expectancy ≥3&#xD;
             months;&#xD;
&#xD;
          -  providing signed and dated informed consents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Usage of rituximab or other anti-CD20 monoclonal antibody within 2 years before&#xD;
             enrollment;&#xD;
&#xD;
          -  usage of hematopoietic cytokines within 1 week before enrollment, e.g. granulocyte&#xD;
             colony stimulating factor (G-CSF);&#xD;
&#xD;
          -  recent major surgery (excluding diagnostic surgery) within the past 8 weeks;&#xD;
&#xD;
          -  peripheral nervous system diseases or central nervous system diseases;&#xD;
&#xD;
          -  inadequate hematologic function met any of the following at screening: white blood&#xD;
             cell count &lt;3.0×109/L, absolute neutrophil count (lobocyte and rhabdocyte) &lt;1.5×109/L,&#xD;
             platelet count &lt;100×109/L, hemoglobin &lt;90 g/L, for patients with bone marrow&#xD;
             involvement, absolute neutrophil count (lobocyte and rhabdocyte) &lt;1.0×109/L, platelet&#xD;
             count &lt;75×109/L, hemoglobin &lt;80 g/L;&#xD;
&#xD;
          -  inadequate liver function met any of the following at screening: total&#xD;
             bilirubin&gt;1.5×the upper limit of normal range (ULN), ALT or AST&gt;2.0×ULN, alkaline&#xD;
             phosphatase (ALP)&gt;3.0×ULN;&#xD;
&#xD;
          -  abnormal renal function (serum creatinine&gt;1.5×ULN);&#xD;
&#xD;
          -  abnormal thyroid function (TSH&lt; lower limit of normal or &gt; upper limit of normal with&#xD;
             clinical significance judged by investigators);&#xD;
&#xD;
          -  positive test result(s) for serum HIV antigen or antibody;&#xD;
&#xD;
          -  seropositivity of HBsAg, or seropositivity of HBcAb and HBV DNA&gt;ULN; seropositivity of&#xD;
             Anti HCV antibody;&#xD;
&#xD;
          -  history of herpes zoster and left with sequelae or latent infection;&#xD;
&#xD;
          -  other serious disease which may restrict subjects to participate in the trial (such as&#xD;
             ongoing active infection, uncontrolled diabetes mellitus, severe cardiac insufficiency&#xD;
             or angina pectoris, gastric ulcer, active autoimmune disease, etc.);&#xD;
&#xD;
          -  pregnancy or breast feeding female, or not willing to use effective contraceptive&#xD;
             measures during the study;&#xD;
&#xD;
          -  allergic constitution, or known allergic to components of rituximab or other anti-CD20&#xD;
             monoclonal antibody;&#xD;
&#xD;
          -  history of alcoholism or drug abuse; participation in other clinical trials within 3&#xD;
             months before enrollment;&#xD;
&#xD;
          -  not suitable for enrollment at investigator's discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

